Fluvoxamine appears to be an effective option for reducing COVID-19 hospitalisations

Embargoed until: Publicly released: 2022-04-07 01:00

International

Photo by Adam Nieścioruk on Unsplash

Fluvoxamine, a drug usually used as an antidepressant, is highly likely to be able to reduce hospitalisations when used early as a COVID-19 treatment, according to an international meta-analysis. The researchers assessed the combined results of three trials including about 2000 participants, and found there was a 94.1 per cent to 98.6 per cent chance the drug had an impact on hospitalisation numbers when used as an early COVID-19 treatment. They say Fluvoxamine could be a more widely accessible option to supplement the use of other treatments particularly where supply is low.

Media release

From:

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page The URL will go live after the embargo ends

Journal/
conference: JAMA Network Open

Research:Paper

Organisation/s: McGill University Health Centre, Canada

Funder: Dr Lee reported receiving personal fees from Fonds de Recherche du Quebec— Sante and grants from the Canadian Institutes Health Research outside the submitted work. Dr Boulware reported receiving grants from the National Institutes of Health (NIH) and serving as the NIH ACTIV-6 trial steering committee co-chair during the conduct of the study. Dr Lenze reported receiving personal fees from IngenioRx, Prodeo, and Boeringer-Ingelheim outside the submitted work. Drs Lenze and Reiersen reported having a patent application filed byWashington University for methods of treating COVID-19 during the conduct of the study. Dr Reiersen reported receiving grants from COVID-19 Early Treatment during the conduct of the study and receiving grants from FastGrants outside the submitted work. Dr McDonald reported receiving financial support for trial recruitment from the University ofWashington during the conduct of the study and receiving personal fees from Fonds de Recherche du Quebec—Sante outside the submitted work. No other disclosures were reported.

Media Contact/s

Contact details are only visible to registered journalists.